Optimal duration of adjuvant endocrine therapy: how to apply the newest data

por Wimmer, Kerstin, Strobl, Stephanie, Bolliger, Michael, Devyatko, Yelena, Korkmaz, Belgin, Exner, Ruth, Fitzal, Florian, Gnant, Michael
Publicado 2017

Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study

por Snijder, Berend, Vladimer, Gregory I, Krall, Nikolaus, Miura, Katsuhiro, Schmolke, Ann-Sofie, Kornauth, Christoph, Lopez de la Fuente, Oscar, Choi, Hye-Soo, van der Kouwe, Emiel, Gültekin, Sinan, Kazianka, Lukas, Bigenzahn, Johannes W, Hoermann, Gregor, Prutsch, Nicole, Merkel, Olaf, Ringler, Anna, Sabler, Monika, Jeryczynski, Georg, Mayerhoefer, Marius E, Simonitsch-Klupp, Ingrid, Ocko, Katharina, Felberbauer, Franz, Müllauer, Leonhard, Prager, Gerald W, Korkmaz, Belgin, Kenner, Lukas, Sperr, Wolfgang R, Kralovics, Robert, Gisslinger, Heinz, Valent, Peter, Kubicek, Stefan, Jäger, Ulrich, Staber, Philipp B, Superti-Furga, Giulio
Publicado 2017